跳至主要内容
临床试验/NCT00411515
NCT00411515已完成4 期

A Prospective Randomized Trial on Mycophenolate Mofetil in Risk Penetrating Keratoplasty

University Hospital Freiburg2 个研究点 分布在 1 个国家开始时间: 2006年12月14日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
试验地点
2

研究概览

简要总结

The purpose of this prospectively randomized multicentre study was to prove the efficacy and safety of mycophenolate mofetil (MMF) to preventing graft rejection and improvement of clear graft survival following high-risk keratoplasty.

The patients of the MMF group receive MMF orally 2x1 g daily for 6 months. Endpoints were immune reaction free and clear graft survival and the occurence of side-effects.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Keratoplasty with increased risk for immunologic graft rejection in the abscence of other risk factors for graft failure. (repeat keratoplasty, steroid-response, limbo-keratoplasty, oversized graft.

排除标准

  • Normal risk cases. Herpes-Keratitis. Glaucoma. Limbus stem cell deficiency.

研究者

发起方
University Hospital Freiburg
申办方类型
Other

研究点 (2)

Loading locations...

相似试验